Make earnings with no risk
Automated AI-driven system makes the trades, you earn the money
Join now

Design Therapeutics Faces Setback in Drug Trial


By Ben Glickman

Design Therapeutics, a clinical-stage biotechnology company, experienced a significant drop in its stock price after patients in a trial of its drug reported injection site reactions. The stock reached its third all-time low in just four days, with shares falling by 2.4% to $2.07.

This recent decline adds to a week of staggering losses for Design Therapeutics, as shares have plummeted by 73%. Over the span of the past 12 months, the company’s stock has shed an alarming 90% of its value.

The Carlsbad, Calif.-based company disclosed that five subjects participating in a phase 1 study of DT-216, the company’s potential treatment for the degenerative disease Friedreich ataxia, developed reactions to the drug. Out of the five reactions, four were categorized as mild, while one was classified as moderate.

Despite these setbacks, Design Therapeutics plans to continue the development of DT-216 based on the trial results. However, the company intends to enhance the drug’s formulation. It aims to commence a new multi-dose phase 1 trial in the second half of 2024, with clinical data anticipated to be available in the first half of 2025.

Elon Musk’s Decision to Remove Block Feature on X Could Impact Its App Store Presence

Previous article

Japan’s Defense Spending: Crucial for Confronting North Korea and China

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News